Robert E. Waltermire - Mar 5, 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Signature
/s/ Mardi Dier, as Attorney-in-Fact
Stock symbol
MDGL
Transactions as of
Mar 5, 2025
Transactions value $
-$3,582,338
Form type
4
Date filed
3/7/2025, 05:40 PM
Previous filing
Mar 4, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $600K +6.83K +183.07% $87.92 10.6K Mar 5, 2025 Direct
transaction MDGL Common Stock Options Exercise $635K +7.29K +69.06% $87.09 17.8K Mar 5, 2025 Direct
transaction MDGL Common Stock Sale -$302K -900 -5.04% $335.15 16.9K Mar 5, 2025 Direct F1
transaction MDGL Common Stock Sale -$598K -1.78K -10.49% $336.78 15.2K Mar 5, 2025 Direct F2
transaction MDGL Common Stock Sale -$387K -1.15K -7.56% $338.09 14K Mar 5, 2025 Direct F3
transaction MDGL Common Stock Sale -$136K -400 -2.85% $339.68 13.6K Mar 5, 2025 Direct F4
transaction MDGL Common Stock Sale -$565K -1.66K -12.17% $340.75 12K Mar 5, 2025 Direct F5
transaction MDGL Common Stock Sale -$357K -1.04K -8.72% $341.84 10.9K Mar 5, 2025 Direct F6
transaction MDGL Common Stock Sale -$369K -1.08K -9.86% $342.90 9.84K Mar 5, 2025 Direct F7
transaction MDGL Common Stock Sale -$1.62M -4.7K -47.77% $343.85 5.14K Mar 5, 2025 Direct F8
transaction MDGL Common Stock Sale -$487K -1.41K -27.47% $344.76 3.73K Mar 5, 2025 Direct F9
transaction MDGL Common Stock Award $0 +2.06K +55.28% $0.00 5.79K Mar 5, 2025 Direct F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -6.83K -60.94% $0.00 4.38K Mar 5, 2025 Common Stock 6.83K $87.92 Direct F11
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -7.29K -70.42% $0.00 3.06K Mar 5, 2025 Common Stock 7.29K $87.09 Direct F12
transaction MDGL Stock Option (Right to Buy) Award $0 +1.16K $0.00 1.16K Mar 5, 2025 Common Stock 1.16K $347.28 Direct F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.005 to $335.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $336.445 to $337.44, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $337.47 to $338.44, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $339.21 to $340.14, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.24 to $341.18, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.24 to $342.05, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.30 to $343.29, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $343.31 to $344.30, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $344.31 to $345.07, inclusive.
F10 Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date.
F11 All shares issued pursuant to the exercise of the options reported herein represent 6,825 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
F12 All shares issued pursuant to the exercise of the options reported herein represent 7,288 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
F13 The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.